Indefinite Delivery Contract 36E79726D0022

Golden State Medical Supply, Inc. has been awarded a single-award Indefinite Delivery Contract by the VA National Acquisition Center for the supply of Buprenorphine HCL/Naloxone HCL sublingual tablets to support multiple federal healthcare systems. The contract, valued at $20.98 million, covers the base ordering period from June 8, 2026, through June 7, 2027, with four one-year option periods extending potential contract performance through June 7, 2030. The specific products procured include Buprenorphine HCL 2mg/Naloxone HCL 0.5mg tablets in 30-count sublingual formulations, with estimated annual requirements of 171,239 bottles, and Buprenorphine HCL 8mg/Naloxone HCL 2mg tablets with estimated annual requirements of 251,144 bottles. This unrestricted competitive procurement was solicited through the VA's electronic commercial item format in accordance with Federal Acquisition Regulation Part 12, with the original solicitation (36E79726R0004) posted on December 31, 2025, with a closing date of January 19, 2026.

The contract's scope encompasses pharmaceutical supply chain support for the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service through the VA's and Department of Defense's Pharmaceutical Prime Vendor Programs, which are designed to ensure uninterrupted supply of critical medications to federal healthcare facilities. Buprenorphine/naloxone combination therapy is used primarily in opioid use disorder treatment and maintenance programs across these federal healthcare systems. As the sole awardee, Golden State Medical Supply is responsible for maintaining consistent inventory and distribution capabilities to meet the combined annual volume of approximately 422,383 bottles. No set-asides were applied to this procurement, indicating the award was made on an unrestricted competitive basis to the responsible offeror deemed most capable of providing reliable, uninterrupted pharmaceutical supply services.